NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a -- dividend on Friday, November 1st. Investors of record on Wednesday, January 15th will be paid a dividend of $1.18 per share on Friday, February 14th. This represents a dividend yield of 5.93%. The ex-dividend date is Tuesday, January 14th. This is an increase from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

AbbVie announced that its board has authorized a share buyback plan on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its shares are undervalued.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, February, 7th. The company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.19 by $0.02. The company earned $8.70 billion during the quarter, compared to the consensus estimate of $8.68 billion. AbbVie had a net margin of 23.69% and a negative return on equity of 162.37%. AbbVie's revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for AbbVie.

AbbVie issued an update on its FY20 earnings guidance on Friday, February, 7th. The company provided EPS guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus estimate of $9.78.

14 analysts have issued 12-month price objectives for AbbVie's stock. Their forecasts range from $66.61 to $104.00. On average, they expect AbbVie's share price to reach $88.72 in the next year. This suggests that the stock has a possible downside of 5.7%. View Analyst Price Targets for AbbVie.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AbbVie.

News coverage about ABBV stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for AbbVie.

Some companies that are related to AbbVie include The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), Allergan (AGN), BioDelivery Sciences International (BDSI), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP), Horizon Therapeutics (HZNP) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.65%), FMR LLC (2.72%), Bank of New York Mellon Corp (1.02%), Renaissance Technologies LLC (0.80%), Charles Schwab Investment Management Inc. (0.47%) and Sumitomo Mitsui Trust Holdings Inc. (0.40%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Skandinaviska Enskilda Banken AB publ , Victory Capital Management Inc., Levin Easterly Partners LLC, Bank of New York Mellon Corp, Bank of Montreal Can, Pinebridge Investments L.P. and Oakbrook Investments LLC. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Farallon Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Amundi Pioneer Asset Management Inc., MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd and Lord Abbett & CO. LLC. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $94.05.

AbbVie has a market capitalization of $139.08 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.